International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors

Edward C. Kuan, Eric W. Wang, Nithin D. Adappa, Daniel M. Beswick, Nyall R. London, Shirley Y. Su, Marilene B. Wang, Waleed M. Abuzeid, Borislav Alexiev, Jeremiah A. Alt, Paolo Antognoni, Michelle Alonso-Basanta, Pete S. Batra, Mihir Bhayani, Diana Bell, Manuel Bernal-Sprekelsen, Christian S. Betz, Jean Yves Blay, Benjamin S. Bleier, Juliana Bonilla-VelezClaudio Callejas, Ricardo L. Carrau, Roy R. Casiano, Paolo Castelnuovo, Rakesh K. Chandra, Vasileios Chatzinakis, Simon B. Chen, Alexander G. Chiu, Garret Choby, Naweed I. Chowdhury, Martin J. Citardi, Marc A. Cohen, Roi Dagan, Gianluca Dalfino, Iacopo Dallan, Camila Soares Dassi, John de Almeida, Angelo P. Dei Tos, John M. DelGaudio, Charles S. Ebert, Ivan H. El-Sayed, Jean Anderson Eloy, James J. Evans, Christina H. Fang, Nyssa F. Farrell, Marco Ferrari, Nancy Fischbein, Adam Folbe, Wytske J. Fokkens, Meha G. Fox, Valerie J. Lund, Gary L. Gallia, Paul A. Gardner, Mathew Geltzeiler, Christos Georgalas, Anne E. Getz, Satish Govindaraj, Stacey T. Gray, Jessica W. Grayson, Bradley A. Gross, Jordon G. Grube, Ruifeng Guo, Patrick K. Ha, Ashleigh A. Halderman, Ehab Y. Hanna, Richard J. Harvey, Stephen C. Hernandez, Adam L. Holtzman, Claire Hopkins, Zhigang Huang, Zhenxiao Huang, Ian M. Humphreys, Peter H. Hwang, Alfred M. Iloreta, Masaru Ishii, Michael E. Ivan, Aria Jafari, David W. Kennedy, Mohemmed Khan, Adam J. Kimple, Todd T. Kingdom, Anna Knisely, Ying Ju Kuo, Devyani Lal, Eric D. Lamarre, Ming Ying Lan, Hien Le, Matt Lechner, Nancy Y. Lee, Jivianne K. Lee, Victor H. Lee, Corinna G. Levine, Jin Ching Lin, Derrick T. Lin, Brian C. Lobo, Tran Locke, Amber U. Luong, Kelly R. Magliocca, Svetomir N. Markovic, Gesa Matnjani, Erin L. McKean, Cem Meço, William M. Mendenhall, Loren Michel, Shorook Na'ara, Piero Nicolai, Daniel W. Nuss, Gurston G. Nyquist, Gretchen M. Oakley, Kazuhiro Omura, Richard R. Orlandi, Nobuyoshi Otori, Peter Papagiannopoulos, Zara M. Patel, David G. Pfister, Jack Phan, Alkis J. Psaltis, Mindy R. Rabinowitz, Murugappan Ramanathan, Ryan Rimmer, Marc R. Rosen, Olabisi Sanusi, Zoukaa B. Sargi, Philippe Schafhausen, Rodney J. Schlosser, Ahmad R. Sedaghat, Brent A. Senior, Raj Shrivastava, Raj Sindwani, Timothy L. Smith, Kristine A. Smith, Carl H. Snyderman, C. Arturo Solares, Satyan B. Sreenath, Aldo Stamm, Katharina Stölzel, Baran Sumer, Pavol Surda, Bobby A. Tajudeen, Lester D.R. Thompson, Brian D. Thorp, Charles C.L. Tong, Raymond K. Tsang, Justin H. Turner, Mario Turri-Zanoni, Aaron M. Udager, Thibaut van Zele, Kyle VanKoevering, Kevin C. Welch, Sarah K. Wise, Ian J. Witterick, Tae Bin Won, Stephanie N. Wong, Bradford A. Woodworth, Peter John Wormald, William C. Yao, Chien Fu Yeh, Bing Zhou, James N. Palmer

Research output: Contribution to journalReview articlepeer-review

Abstract

Background: Sinonasal neoplasms, whether benign and malignant, pose a significant challenge to clinicians and represent a model area for multidisciplinary collaboration in order to optimize patient care. The International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors (ICSNT) aims to summarize the best available evidence and presents 48 thematic and histopathology-based topics spanning the field. Methods: In accordance with prior International Consensus Statement on Allergy and Rhinology documents, ICSNT assigned each topic as an Evidence-Based Review with Recommendations, Evidence-Based Review, and Literature Review based on the level of evidence. An international group of multidisciplinary author teams were assembled for the topic reviews using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses format, and completed sections underwent a thorough and iterative consensus-building process. The final document underwent rigorous synthesis and review prior to publication. Results: The ICSNT document consists of four major sections: general principles, benign neoplasms and lesions, malignant neoplasms, and quality of life and surveillance. It covers 48 conceptual and/or histopathology-based topics relevant to sinonasal neoplasms and masses. Topics with a high level of evidence provided specific recommendations, while other areas summarized the current state of evidence. A final section highlights research opportunities and future directions, contributing to advancing knowledge and community intervention. Conclusion: As an embodiment of the multidisciplinary and collaborative model of care in sinonasal neoplasms and masses, ICSNT was designed as a comprehensive, international, and multidisciplinary collaborative endeavor. Its primary objective is to summarize the existing evidence in the field of sinonasal neoplasms and masses.

Original languageEnglish (US)
Pages (from-to)149-608
Number of pages460
JournalInternational Forum of Allergy and Rhinology
Volume14
Issue number2
DOIs
StatePublished - Feb 2024

Keywords

  • adenocarcinoma
  • adenoid cystic carcinoma
  • adjuvant therapy
  • angiofibroma
  • biopsy
  • chemotherapy
  • concurrent
  • endoscopic endonasal approach
  • esthesioneuroblastoma
  • evidence-based medicine
  • head and neck cancer
  • head and neck oncology
  • immunotherapy
  • induction chemotherapy
  • inverted papilloma
  • lymphoma
  • margins
  • metastases
  • mucosal melanoma
  • nasopharyngeal carcinoma
  • neoadjuvant therapy
  • neuroectodermal carcinoma
  • neuroendocrine carcinoma
  • olfactory neuroblastoma
  • open approach
  • orbit
  • papilloma
  • quality of life
  • radiation
  • resectability
  • rhabdomyosarcoma
  • risk factors
  • sarcoma
  • sinonasal cancer
  • sinonasal malignancy
  • sinonasal neoplasm
  • sinonasal oncology
  • sinonasal papilloma
  • sinonasal tumor
  • sinonasal undifferentiated carcinoma
  • skull base
  • squamous cell carcinoma
  • surgery
  • surveillance
  • survival
  • survivorship

ASJC Scopus subject areas

  • Immunology and Allergy
  • Otorhinolaryngology

Fingerprint

Dive into the research topics of 'International Consensus Statement on Allergy and Rhinology: Sinonasal Tumors'. Together they form a unique fingerprint.

Cite this